Evaluate the diagnostic and prognostic value of NUSAP1 in papillary thyroid carcinoma and identify the relationship with genes, proteins, and immune factors

• Published in: World journal of surgical oncology 2022-06, Vol.20 (1), p.1-207, Article 207
• Main Authors: Gao, Tiantian, Zhao, Lei, Zhang, Fan, Cao, Conghui, Fan, Shuting, Shi, Xiaoguang
• Format: Article
• Language: English
• Subjects: Autoimmune diseases; Binding proteins; Cancer; Cancer therapies; Cell cycle; Cell division; Cell growth; Datasets; Diabetes; Diagnosis; Diagnostic systems; Drug delivery; Gastric cancer; Gene expression; Genes; Genetic aspects; Health aspects; Immune checkpoint inhibitors; Immune response; Immune system; Immunosuppressive agents; Immunotherapy; Kinases; Lymph nodes; Medical prognosis; Metastases; mRNA; Nucleoli; NUSAP1; Oncology, Experimental; Papillary thyroid carcinoma; Prognosis; Prognostic markers; Proteins; Risk analysis; Risk factors; Survival; Survival analysis; Thyroid; Thyroid cancer; Tumor immunity; Tumor microenvironment; Tumors; Websites
• ISSN: 1477-7819; 1477-7819
• DOI: 10.1186/s12957-022-02652-9

Background Nucleolar spindle-associated protein 1 (NUSAP1) is reported to be a useful diagnostic and prognostic marker for a variety of cancers, but relevant studies are lacking in papillary thyroid carcinoma (PTC). Methods The relationship between NUSAP1 expression and the overall survival (OS) of pan-cancer was examined by GEPIA and KMplot. We explored the relationship between NUSAP1 and clinical PTC data based on the THCA dataset of TCGA and the GEO dataset of NCBI; GO, KEGG analysis, and ceRNA networks were performed on co-expressed genes through LinkedOmics and Starbase. We assessed the relevance between NUSAP1 and the tumor microenvironment using ESTIMATE, correlations between NUSAP1 and immune cells with TIMER, the relationship between NUSAP1 and immunotherapy by TCIA, and small-molecule drugs targeting NUSAP1 that can be discovered using the CMap database. Results Higher expression of NUSAP1 in pan-cancer tissues was correlated with shorter OS. NUSAP1 was also significantly expressed in PTC tissues and was an independent prognostic risk factor. Compared to the NUSAP1 low expression group, the NUSAP1 high expression group was more likely to also have lymph node metastasis, pathological PTC type, shorter progression-free survival (PFS), and higher scores for immune checkpoint inhibitor treatment. The genes associated with NUSAP1 were mostly involved in the cell cycle, immune-related pathways, and AITD. Ten lncRNAs (GAS5, SNHG7, UCA1, SNHG1, HCP5, DLEU2, HOTAIR, TP53TG1, SNHG12, C9orf106), eleven miRNAs (hsa-miR-10a-5p, hsa-miR-10b-5p, hsa-miR-18a-5p, hsa-miR-18b-5p, hsa-miR-128-3p, hsa-miR-214-3p, hsa-miR-219a-2-3p, hsa-miR-339-5p, hsa-miR-494-3p, hsa-miR-545-3p, hsa-miR-769-5p), and one mRNA (NUSAP1) were constructed. NUSAP1 participated in the formation of the tumor microenvironment. CMap predicted the 10 most important small molecules about NUSAP1. Conclusions In PTC, NUSAP1 shows good diagnostic value and prognostic value; NUSAP1 impacts the cell cycle, immune-related pathways, and AITD and has a complex effect on the tumor microenvironment in PTC. Keywords: NUSAP1, Papillary thyroid carcinoma, Prognostic markers, Tumor immunity